Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in ulcerative colitis maintenance
NCT03398135Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 43
01
Overview
A Phase 3 trial of risankizumab in ulcerative colitis (UC), sponsored by AbbVie Inc.. Started Aug 2018; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03398135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398135.